Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1)
Blockage of collagen binding to integrin alpha 2 beta 1: structure-activity relationship of protein-protein interaction inhibitors
Julkaisun tekijät: Koivunen JT, Nissinen L, Juhakoski A, Pihlavisto M, Marjamaki A, Huuskonen J, Pentikainen OT
Kustantaja: ROYAL SOC CHEMISTRY
Julkaisuvuosi: 2011
Journal: MedChemComm
Tietokannassa oleva lehden nimi: MEDCHEMCOMM
Lehden akronyymi: MEDCHEMCOMM
Volyymi: 2
Julkaisunumero: 8
Aloitussivu: 764
Lopetussivun numero: 770
Sivujen määrä: 7
ISSN: 2040-2503
DOI: http://dx.doi.org/10.1039/c1md00089f
Tiivistelmä
The interaction between the alpha 2 beta 1 integrin and collagen plays a crucial role in the development of pathological conditions, such as thrombus formation and cancer cell metastasis. Accordingly, the alpha 2 beta 1 integrin is a promising target for the development of new drug molecules to treat these diseases. Here, we have designed, synthesized, and measured in vitro a set of novel drug-like compounds that block the protein-protein interactions between alpha 2 beta 1 integrin and collagen. The obtained structure-activity relationship reveals the key features that are required for successful inhibition of this integrin-collagen interaction.
The interaction between the alpha 2 beta 1 integrin and collagen plays a crucial role in the development of pathological conditions, such as thrombus formation and cancer cell metastasis. Accordingly, the alpha 2 beta 1 integrin is a promising target for the development of new drug molecules to treat these diseases. Here, we have designed, synthesized, and measured in vitro a set of novel drug-like compounds that block the protein-protein interactions between alpha 2 beta 1 integrin and collagen. The obtained structure-activity relationship reveals the key features that are required for successful inhibition of this integrin-collagen interaction.
Turun yliopiston Tutkimustietojärjestelmän portaali